Betaine And Homocysteine — The Methyl Donor Nobody Mentions
Quick Read Your body has two separate systems for recycling homocysteine, an amino acid that builds up after you eat
We write a new article on supplements every day , all detailed, with citations.
Once a week we send an email containing a list of the last 7 days articles. Please sign up and also feel free to share the articles with friends and family who you think might benefit.
Simon Parrott – Vitacuity Ltd
Ashwagandha, a traditional Indian herb, is being studied for its potential to reduce amyloid-beta plaques, the sticky protein deposits linked to Alzheimer’s disease. Lab and animal studies show it may work through multiple mechanisms: helping the liver remove amyloid from the brain, preventing amyloid clumping into plaques, and protecting neurons from damage. One small human trial found that 250 mg daily of ashwagandha extract improved cognitive scores by up to 19 percent in people with mild memory problems over 60 days, which is notable but needs confirmation in larger studies.
The evidence is genuinely interesting but mostly limited to mouse studies and lab tests. No human trial has yet proven that ashwagandha actually reduces amyloid plaques in people’s brains. Mice are not humans, and many promising compounds have failed in human trials after working in animals. The one human cognitive study was small, lasted only two months, and used a standardised extract at a specific dose.
For healthy adults in their 40s and 50s concerned about brain health, ashwagandha appears to be a reasonable choice given the preclinical science, the cognitive benefits seen in early human testing, and its good safety record. Look for standardised extracts, expect results to take weeks rather than days, and understand this is not a proven Alzheimer’s treatment. Anyone with symptoms of cognitive decline should seek medical evaluation first.
Verdict: Ashwagandha shows genuinely promising mechanisms for brain protection in animal and lab studies, plus encouraging early human data on memory improvement, but human proof that it prevents or slows Alzheimer’s does not yet exist.
What if one of the most promising leads in Alzheimer’s research wasn’t sitting in a pharmaceutical lab, but had been quietly growing in the dry soils of India for thousands of years? That’s not a rhetorical flourish, it’s a question that a growing body of preclinical research is forcing scientists to take seriously. Ashwagandha (*Withania somnifera*), the adaptogenic root that Ayurvedic practitioners have used for centuries as a nerve tonic and memory enhancer, is now being examined for something far more ambitious than stress relief: its potential to reduce amyloid-beta plaques, the sticky protein deposits that are one of the defining hallmarks of Alzheimer’s disease. Let’s be clear from the outset: almost all of this research is preclinical. We’re looking at mouse models and lab studies, not large human trials. But the *mechanisms* being uncovered are genuinely intriguing, and the human data on cognitive function, while early, is encouraging enough to take seriously. Vitacuity has analysed over 1.77 million research papers and selected the most relevant 15 for this topic. Here’s what they actually say.
To understand why ashwagandha’s effects on amyloid are interesting, you first need to understand what amyloid-beta actually is and why it’s so hard to shift.
Amyloid-beta (Aβ) is a small protein fragment that’s produced naturally in the brain throughout your life. In healthy brains, it gets cleared away efficiently. In Alzheimer’s disease, this clearance system breaks down. The fragments accumulate, clump together into oligomers (small toxic clusters), and eventually form the hard plaques that can be seen in post-mortem brain tissue. These plaques trigger inflammation, disrupt communication between neurons, and are associated with the cognitive decline that defines the disease [3].
The challenge with most Alzheimer’s treatments is that they tend to work on a single target, blocking a particular enzyme or receptor, while the disease operates across multiple pathways simultaneously: amyloid accumulation, tau tangles, neuroinflammation, oxidative stress, and breakdown of the cholinergic system [3]. This is one reason why pharmaceutical approaches have such a difficult track record.
Ashwagandha’s active compounds, primarily withanolides and withanosides, appear to interact with *several* of these pathways at once [4]. That’s what makes it scientifically interesting, even if human evidence is still catching up with the preclinical data.
One of the most fascinating findings in this area comes from a 2012 study published in *PNAS* [7], which identified a mechanism that almost nobody had thought to look at before: the liver.
Researchers administered a semipurified ashwagandha root extract, containing predominantly withanolides and withanosides, orally to two different transgenic mouse models of Alzheimer’s disease (APP/PS1 mice and APPSwInd “J20” mice) for 30 days [7]. The results were striking in both models: reversal of behavioural deficits, reduction in plaque pathology, and a measurable decrease in amyloid-beta peptides and oligomers in the brain.
What made this study genuinely novel was *how* it appeared to work. Within just 7 days, plasma Aβ levels rose while brain Aβ levels fell, suggesting that amyloid was being transported *out* of the brain and into the bloodstream [7]. The mechanism traced back to the liver: ashwagandha extract significantly upregulated a protein called LRP (low-density lipoprotein receptor-related protein) in the liver, along with a peptide-degrading enzyme called neprilysin (NEP). The liver LRP produced a soluble form called sLRP that circulates in the blood and acts as a “peripheral sink”, essentially drawing amyloid away from the brain [7].
Crucially, when the researchers selectively blocked liver LRP (but not NEP), the therapeutic effects disappeared, confirming that liver LRP upregulation was the key driver, not just a coincidence [7].
Evidence grade: Early stage. This is a rodent study. The mechanism is elegant and the effect sizes are meaningful, but it has not yet been replicated in human trials. The finding that the liver, not just the brain, plays a role in amyloid clearance is conceptually important and has generated significant scientific interest [12].
A separate line of research has looked not at clearing amyloid that’s already formed, but at preventing the clumping process in the first place.
A 2012 in vitro study [14] tested whether an aqueous extract of ashwagandha root could inhibit amyloid-beta fibril formation, the process by which individual Aβ peptides stack together into the fibrous structures that eventually become plaques. Using transmission electron microscopy and a fluorescence assay (ThT), the researchers found that the extract *strongly* inhibited Aβ fibril formation in a concentration-dependent manner, meaning the more extract was used, the greater the inhibition [14].
This was supported by a 2020 study [10] that used fluorescence spectroscopy to screen four traditional Ayurvedic nutraceuticals, including ashwagandha, against three variants of the amyloid-beta peptide (methionine Aβ1-40, Aβ1-40, and Aβ1-42). All samples showed inhibitory activity across all three Aβ variants [10]. The researchers noted that the potential benefit of such compounds includes “preventing pathogen plaque formation and reducing free Aβ to a natural level” [10].
Evidence grade: Early stage. These are laboratory (in vitro) studies, not animal or human trials. They tell us the chemistry is plausible, that ashwagandha extracts can physically interact with amyloid peptides to prevent fibril formation, but they don’t tell us whether this happens in a living body at realistic doses.
Several studies have used transgenic mouse models, mice genetically engineered to develop Alzheimer’s-like pathology, to test whether ashwagandha can reduce amyloid burden in a living system.
A 2024 study [8] used the 5xFAD mouse model, which develops aggressive amyloid pathology, and found that ashwagandha supplementation improved spatial memory, reduced anxiety and depressive-like behaviour, and was associated with reduced beta-amyloid accumulation and markers of neuroinflammation and oxidative stress [8].
A 2025 study [1] combined ethanolic ashwagandha extract (E-ASH) with water-soluble CoQ10 (Ubisol-Q10) in a transgenic mouse model of AD. The combination treatment produced “a substantial reduction in microglial activation and amyloid-β plaques” [1]. Beyond amyloid, the combination group also showed elevated BDNF (brain-derived neurotrophic factor, a key molecule for neuronal health and plasticity), increased neuronal nuclei density, and enhanced synaptic vesicle formation [1]. Memory tests conducted before the mice were culled confirmed that cognitive abilities were better preserved in treated animals [1].
This same study [1] found that autophagy, the brain’s cellular “housekeeping” process that breaks down and recycles damaged proteins, was upregulated in the CoQ10 group and the combination group. This is relevant because impaired autophagy is thought to contribute to amyloid accumulation in the first place.
A 2025 review [3] also highlighted the role of ashwagandha’s primary active compounds, withanolides, in targeting neuroinflammation and oxidative stress, both of which amplify amyloid pathology and neuronal damage in Alzheimer’s disease.
Evidence grade: Early stage. Multiple transgenic mouse studies show consistent findings, reduced amyloid, improved cognition, reduced neuroinflammation. The consistency across different models and research groups is encouraging. But mice are not humans, and the history of Alzheimer’s research is littered with compounds that worked brilliantly in rodent models and failed in human trials.
A 2014 lab study [6] tested whether ashwagandha extract and its purified constituent Withanolide A could protect human neuronal cells (SK-N-MC cell line) against Aβ-induced toxicity directly. When amyloid-beta (1-42) was applied to these cells alone, it caused significant cytotoxic damage. When ashwagandha extract was added alongside the amyloid, the toxic effects were “neutralised” [6]. The researchers also measured acetylcholinesterase activity, relevant because cholinergic dysfunction is a feature of Alzheimer’s, and found that ashwagandha’s protective effects extended to this pathway as well [6].
This adds a third mechanism to the picture: not just clearing amyloid and preventing fibril formation, but actually protecting neurons from the damage amyloid causes once it’s present.
Evidence grade: Early stage. This is a cell culture study using human neuronal cells, one step closer to human relevance than mouse studies, but still far from a clinical trial.
While the amyloid-clearance research is largely preclinical, there *is* human trial data showing that ashwagandha improves cognitive function, particularly in people who already have measurable cognitive decline.
A 2025 randomised, double-blind, placebo-controlled pilot trial [2] enrolled 40 adults with mild cognitive impairment (MCI), a condition often considered a precursor to Alzheimer’s disease. Participants received either 250 mg/day of a standardised ashwagandha extract (Somin-On™, standardised with Sominone) or a placebo for 60 days. They were assessed using four validated cognitive tools: the Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), Wechsler Memory Scale-III (WMS-III), and a Shepard Mental Rotation Task [2].
The results were notable: – MoCA scores improved by 7.83% at 30 days and 14.77% at 60 days from baseline in the ashwagandha group, significantly outperforming placebo [2] – MMSE scores improved by 9.26% at 30 days and 19.21% at 60 days [2] – The Shepard Mental Rotation test showed a 31.67% improvement at 60 days from baseline [2] – Significant improvements were also seen in immediate memory, general memory, working memory, visuospatial processing, attention and information processing speed [2]
This is genuinely meaningful data. The improvements on the MMSE and MoCA aren’t trivial, these are validated clinical tools used to diagnose and monitor dementia progression. A ~19% improvement in MMSE score after just 60 days at 250 mg/day is an effect size worth paying attention to.
Evidence grade: Promising. This is a randomised, double-blind, placebo-controlled trial, the right methodology. But the sample size is only 40 participants, the duration is just 60 days, and it’s a pilot study. We need larger, longer trials before we can draw firm conclusions. The effect sizes are striking, but small trials sometimes overestimate effects.
A 2025 comprehensive review [4] of ashwagandha’s ageing-related benefits confirms that “trials have consistently shown its ability to improve cognitive function, including memory and information-processing speed, particularly in adults with mild cognitive impairment”, while also noting that “large-scale, long-term clinical trials using standardised extracts are essential to fully confirm its role in healthy ageing” [4].
This is where we need to be genuinely honest, because the gap between preclinical excitement and proven human benefit is wide, and in Alzheimer’s research specifically, it has swallowed many promising candidates before.
The human amyloid data doesn’t exist yet. Every study showing amyloid plaque reduction, LRP upregulation, or fibril inhibition was conducted in mice or in lab dishes. We do not have a human trial demonstrating that ashwagandha reduces amyloid burden in the brains of people with Alzheimer’s or MCI. That’s the crucial missing piece.
Mouse models of Alzheimer’s are imperfect. Transgenic AD mice are engineered to develop amyloid pathology rapidly, they don’t fully replicate the slow, multi-decade disease process in humans. Many compounds that clear amyloid in transgenic mice have failed in human trials, including several pharmaceutical monoclonal antibodies with far greater resources behind them [3].
Extract standardisation is a real problem. The studies use different extracts: ethanolic [1], aqueous [14], semipurified withanolide-rich [7], and various commercial standardised preparations [2]. The doses, withanolide concentrations, and extraction methods vary significantly. We don’t know which extract, at which dose, produces which effects, or whether a typical commercial supplement contains the relevant compounds at meaningful concentrations.
The MCI trial is small. 40 participants over 60 days is a pilot study [2]. It’s hypothesis-generating, not conclusive. The effect sizes are impressive enough to warrant a large, long-duration RCT, but that trial hasn’t been done yet.
Long-term safety in older adults hasn’t been rigorously studied. Ashwagandha has a strong traditional safety record and is generally well-tolerated, but formal long-term safety data in populations over 65, particularly those on multiple medications, is limited [4].
We don’t know if cognitive improvements in MCI translate to reduced Alzheimer’s risk. Improving memory test scores in the short term doesn’t automatically mean you’re slowing the underlying disease process. These might be independent effects.
Here’s how a sensible, well-informed person should think about this evidence.
The Alzheimer’s angle is real science, not hype. The LRP liver mechanism [7], the fibril inhibition data [14], the transgenic mouse studies [1, 8], and the cell-based neuroprotection work [6] all point in the same direction: ashwagandha’s active compounds interact with multiple pathways implicated in Alzheimer’s disease in meaningful ways. The human cognitive data in MCI, while from a small trial, shows effect sizes that are hard to dismiss [2].
But we’re not at the point where anyone can tell you that taking ashwagandha will prevent Alzheimer’s. That claim is not supported by the evidence. What we can say is:
1. If you’re 40-65 and concerned about cognitive health, ashwagandha is a rational choice. The human evidence for improved memory and cognitive function, even in people with existing mild impairment, is promising [2, 4]. The preclinical mechanisms are plausible and consistent [1, 3, 7, 14]. The safety profile is good. The cost is low.
2. Look for standardised extracts. The trial showing the most impressive human cognitive results used a standardised extract at 250 mg/day [2]. The preclinical work used withanolide-rich preparations [7]. Standardisation matters, a generic “ashwagandha powder” at unknown withanolide concentration is not the same thing.
3. Don’t expect overnight results. The human trial ran for 60 days, with measurable improvements at both 30 and 60 days [2]. The mouse studies used 30-day protocols [7]. This isn’t a supplement you take for a week and notice a difference.
4. Ashwagandha is not a standalone Alzheimer’s treatment. If you or someone you love has symptoms of cognitive decline, that requires medical assessment, full stop. But for healthy adults in their 40s and 50s thinking about long-term brain protection, the risk/benefit calculation here is genuinely favourable.
5. The combination angle is worth watching. The 2025 study combining ashwagandha with CoQ10 [1] showed enhanced effects compared to either compound alone, including elevated BDNF and better synaptic health. This synergistic approach is scientifically logical given the multiple mechanisms involved, though it needs human validation.
The honest summary: ashwagandha is one of the more scientifically credible herbal compounds for brain health and healthy ageing. The amyloid story is compelling preclinical science. The human cognitive data is genuinely promising. The gap between the two is real, and being honest about that gap is what separates Vitacuity from the brands that would have already put “PROVEN ALZHEIMER’S PREVENTION” on the label. We won’t do that. But we’ll also tell you clearly: the evidence here is interesting enough to act on, intelligently, and with realistic expectations.
[1] Investigation into Efficacy and Mechanisms of Neuroprotection of Ashwagandha Root Extract and Water-Soluble Coenzyme Q10 in a Transgenic Mouse Model of Alzheimer’s Disease (2025). DOI: 10.3390/nu17162701 | https://pubmed.ncbi.nlm.nih.gov/40871729/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12389564/
[2] Effect of Ashwagandha (*Withania somnifera*) standardised with Sominone on memory and cognitive functioning in adults with mild cognitive impairment (2025). DOI: 10.1177/02698811251324377 | https://pubmed.ncbi.nlm.nih.gov/40099725/
[3] Preclinical Evidence of Ashwagandha and Cordyceps Neuroprotective Activity in Alzheimer’s Disease (2025). DOI: 10.3390/ijms26115403 | https://pubmed.ncbi.nlm.nih.gov/40508211/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12156217/
[4] Enhancing healthspan with Ashwagandha (*Withania somnifera*): a comprehensive review of its multifaceted geroprotective benefits (2025). DOI: 10.1007/s10522-025-10320-0 | https://pubmed.ncbi.nlm.nih.gov/40921883/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417257/
[5] Exploring the neuroprotective role of *Asparagus racemosus* in Alzheimer’s disease (2025). DOI: 10.1007/s13205-025-04355-w | https://pubmed.ncbi.nlm.nih.gov/40454371/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125427/
[6] β-Amyloid1-42, HIV-1Ba-L (clade B) infection and drugs of abuse induced degeneration in human neuronal cells and protective effects of ashwagandha (*Withania somnifera*) and its constituent Withanolide A (2014). DOI: 10.1371/journal.pone.0112818 | https://pubmed.ncbi.nlm.nih.gov/25415340/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240587/
[7] Withania somnifera reverses Alzheimer’s disease pathology by enhancing low-density lipoprotein receptor-related protein in liver (2012). https://pubmed.ncbi.nlm.nih.gov/22308347/
[8] *Withania somnifera* (Ashwagandha) Improves Spatial Memory, Anxiety and Depressive-like Behavior in the 5xFAD Mouse Model of Alzheimer’s Disease (2024). DOI: 10.3390/antiox13101164 | https://pubmed.ncbi.nlm.nih.gov/39456417/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11504317/
[9] Effects of Ashwagandha (roots of *Withania somnifera*) on neurodegenerative diseases (2014). DOI: 10.1248/bpb.b14-00022 | https://pubmed.ncbi.nlm.nih.gov/24882401/
[10] Screening of Nutraceuticals and Plant Extracts for Inhibition of Amyloid-β Fibrillation (2020). DOI: 10.3233/JAD-190758 | https://pubmed.ncbi.nlm.nih.gov/31884466/
[11] Investigation into Efficacy and Mechanisms of Neuroprotection of Ashwagandha Root Extract and Water-Soluble Coenzyme Q10 in a Transgenic Mouse Model of Alzheimer’s Disease (2025) [duplicate record]. DOI: 10.3390/nu17162701 | https://pubmed.ncbi.nlm.nih.gov/40871729/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12389564/
[12] Extracting β-amyloid from Alzheimer’s disease (2012). https://pubmed.ncbi.nlm.nih.gov/22328154/
[13] Bacopa monniera extract reduces amyloid levels in PSAPP mice (2006). https://pubmed.ncbi.nlm.nih.gov/16914834/
[14] An aqueous extract of *Withania somnifera* root inhibits amyloid β fibril formation in vitro (2012). https://pubmed.ncbi.nlm.nih.gov/21567509/
[15] Reductions in levels of the Alzheimer’s amyloid beta peptide after oral administration of ginsenosides (2006). DOI: 10.1096/fj.05-5530fje | https://pubmed.ncbi.nlm.nih.gov/16636099/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Your body has two separate systems for recycling homocysteine, an amino acid that builds up after you eat
Quick Read B vitamins become increasingly important for brain health after 40 because your body absorbs them less efficiently with
The nutrients that matter, the forms that work, and the claims to ignore.
